OCULEX PHARMACEUTICALS, INC.


Oct 16, 03

19:10 ET Allergan Announces Agreement to Acquire Oculex Pharmaceuticals, Inc.

 
May 08, 03

08:16 ET Oculex Announces Positive Clinical Results for Posurdex(R) - The First Biodegradable Ocular Implant in Clinical Trial

 
Apr 03, 03

07:31 ET Oculex Pharmaceuticals to Announce Preliminary Phase 2 Efficacy and Safety Results for Posurdex(R) at ARVO

 
Mar 31, 03

07:31 ET Oculex Pharmaceuticals to Present at the BioCentury 'Future Leaders in the Biotech Industry' Conference

 
Dec 04, 02

13:17 ET Oculex Pharmaceuticals Completes Patient Enrollment in Phase 2 Clinical Trial For Persistent Macular Edema Treatment

 
Oct 22, 02

09:06 ET Oculex Pharmaceuticals Raises $50 Million Through Private Financing

 
Oct 29, 01

07:31 ET Oculex Pharmaceuticals Begins Phase II Clinical Trial of Posurdex For Persistent Macular Edema

 
May 21, 01

16:38 ET Allergan and Oculex Enter Into Collaboration for Novel Drug Delivery Technology in the Back-of-the-Eye Ophthalmic Arena

 
Jan 19, 01

14:38 ET Oculex Pharmaceuticals Adds Stanford Chairman of Ophthalmology To Board of Directors

 
Jan 31, 00

16:14 ET Oculex Pharmaceuticals to Formulate Allergan Compounds Using DDS(R) Technology

 


Issuers of news releases and not PR Newswire are solely responsible for the accuracy of the content.
Terms and conditions, including restrictions on redistribution, apply.
Copyright © 1996-2005 PR Newswire Association LLC. ALL Rights Reserved.
A United Business Media company.